Filing Flows › Keros Therapeutics (KROS) › Free cash flow
Keros Therapeutics (KROS) free cash flow by quarter
Keros Therapeutics' free cash flow was $3.3M in Q3 2026 (third quarter 2026), +7% from Q3 2025. Over the last 3 quarters it ranged from $3.1M (Q3 2025) to $161M (Q1 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.3M | +7% | +7% |
| Q3 2025 | $3.1M | -98% | — |
| Q1 2025 | $161M | — | — |
Q3 2026 at a glance
Keros Therapeutics, Q3 2026: revenue $40.0M (+183% year over year), operating margin 32.0%, net earnings $14.2M, operating cash flow $3.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Keros Therapeutics' free cash flow?
Keros Therapeutics' free cash flow was $3.3M in Q3 2026 (third quarter 2026), +7% from Q3 2025.
How has Keros Therapeutics' free cash flow changed?
Over the last 3 quarters it ranged from $3.1M (Q3 2025) to $161M (Q1 2025).